Photo by National Cancer Institute on Unsplash
The $81 Billion Program Congress Is Finally Tackling
It's the afternoon of June 25, 2026. Senator Bill Cassidy's office releases a discussion draft that healthcare lawyers and hospital finance teams have been bracing for since roughly 2011 — the last time Congress meaningfully touched the 340B drug pricing program. By the time Holland & Knight's Health Dose briefing landed on June 30, 2026, as reported by Google News, the week had stacked up into one of the densest healthcare policy stretches in recent memory: a major drug program overhaul, a Medicare payment rate proposal affecting 7,600 facilities, a hospital transparency bill, a 105-page Democratic oversight report, and a new FDA initiative designed to claw back ground lost to China in clinical trial volume. Each item would be significant on its own. Together, they sketch the outline of a healthcare system under simultaneous pressure from every direction.
The 340B program was created to help safety-net providers — hospitals that serve large shares of low-income patients, federally qualified health centers, and similar institutions — stretch their drug budgets. Manufacturers sell covered drugs to qualifying providers at mandated discounts; providers then dispense those drugs and use the margin to fund additional care. Straightforward in theory. In practice, as of 2024, the program now encompasses more than 42,000 covered entities across 53,000-plus care sites, with drug purchases reaching $81 billion, up from $66.3 billion in 2023, according to data from HRSA and the Senate HELP Committee. That's a 22% single-year jump in a program that didn't exist in its current form before 1992.
Chart: 340B drug purchases jumped $14.7 billion in a single year — from $66.3 billion in 2023 to $81 billion in 2024 — accelerating pressure on Congress to act.
What Cassidy's Draft Would Actually Change
Cassidy's discussion draft — framed as the first statutory update since 2011 — contains three provisions that hospital administrators are reading very carefully. First, manufacturers would gain an option to provide a rebate after the point of sale rather than a discount at the time of purchase, a structural change that shifts cash flow timing and administrative burden. Second, covered entities would face a cap of five contract pharmacies (third-party pharmacies authorized to dispense 340B drugs on behalf of a covered entity) — a hard ceiling where none currently exists in federal statute. Third, violations could trigger penalties reaching double the original discount amount.
Cassidy described the proposal as "commonsense solutions to improve 340B for patients," pointing to Congressional Budget Office findings suggesting that misaligned financial incentives embedded in the current structure have contributed to rising medication and insurance costs over time. Critics — particularly large health systems — are focused on the contract pharmacy cap, which would curtail a business model many have built over the past decade.
This proposal arrives against a backdrop of serious legal turbulence. The Fourth Circuit Court of Appeals blocked West Virginia's 340B contract pharmacy protection law in March 2026, creating a circuit split with the Fifth Circuit's ruling on Mississippi's similar statute. Twenty-one states have enacted comparable legislation, all of which now face uncertain federal preemption questions. In February 2026, a federal district court vacated HRSA's own voluntary 340B Rebate Model Pilot Program just weeks after its scheduled January 2026 launch for Medicare-negotiated drugs. The program is essentially being litigated from every angle simultaneously — which is part of why a statutory reset has become difficult to avoid.
Photo by Virginia Commonwealth University Libraries on Unsplash
Three Other Developments That Landed in the Same Week
The simultaneous arrival of additional major healthcare actions made the June 25–30, 2026 window unusual even by Washington standards.
Medicare dialysis payment rates. CMS proposed raising the base per-treatment payment rate for end-stage renal disease (ESRD) — kidney failure requiring regular dialysis — to $299.55 for calendar year 2027, up from $281.71 in CY 2026. That $17.84 per-session increase includes a $15.96 adjustment to account for phosphate binders, a drug class now folded into the bundled payment. Approximately 7,600 dialysis facilities would be affected, with CMS projecting total payments of $6.2 billion. Freestanding facilities would see a 1.1% aggregate payment increase; hospital-based facilities, 2.0%. Acute kidney injury (AKI) dialysis payments would increase 6.0%. These are proposed figures pending a public comment period and final rulemaking.
Nonprofit hospital transparency. The House Committee on Energy and Commerce advanced 15 health-related bills on June 25, 2026, including H.R. 9504, the Tax Exempt Hospital Transparency Act. The bill targets nonprofit hospitals with more than 100 beds or more than $100 million in patient revenue, requiring them to file significantly expanded Schedule H reports with the IRS — essentially more detailed public accounting of how they justify their tax-exempt status. The American Hospital Association, in a June 30, 2026 statement, said the legislation "does not yet strike the right balance," acknowledging improvements from an earlier draft while flagging concerns about the scope of expanded reporting requirements.
FDA clinical trial reform and China competition. HHS launched Operation Trailblazer on June 22, 2026, targeting FDA clinical trial approvals with a projected time savings of six to twelve months per trial. The FDA followed up on June 26, 2026, by launching a Phase 1 IND (Investigational New Drug) Navigator webpage, consolidating resources from CDER (Center for Drug Evaluation and Research) and CBER (Center for Biologics Evaluation and Research) into a single entry point for trial applicants. The urgency behind this initiative is concrete: China surpassed the United States in total registered clinical trials as of data current through 2026 — with more than 7,100 trials representing 39% of global activity — and overtook U.S. Phase 1 trial volume beginning in 2021.
Why the Financial Stakes Extend Beyond Healthcare Stocks
Healthcare represents roughly one-sixth of U.S. GDP, and when Congress, CMS, and HHS move simultaneously on multiple structural issues, the downstream effects reach employers, insurers, pharmaceutical manufacturers, and anyone with broad market exposure through their investment portfolio.
The 340B revenue question matters because many large health systems have come to treat 340B margin as a meaningful cross-subsidy — money that funds services that don't directly generate revenue. A five-contract-pharmacy cap would squeeze those revenue streams at the same moment hospitals are absorbing Medicaid funding reductions from 2025 Republican tax legislation and facing potential site-neutral payment reforms (which would equalize what CMS pays for the same procedure regardless of whether it happens in a hospital outpatient department or a physician's office). These pressures don't arrive sequentially; they stack.
On the Medicare Advantage side, MedPAC's June 2026 Report estimated that Medicare spends 14% more — or $76 billion annually — for Medicare Advantage enrollees compared to traditional Medicare. That structural overpayment has survived multiple reform attempts but remains a recurring target. And the first round of Medicare drug price negotiations — covering 10 high-cost medications — is expected to generate $1.5 billion in savings in 2026, according to MedPAC. Separately, as of July 1, 2026, CMS is launching the Medicare GLP-1 Bridge Program, opening the first coverage pathway for weight-loss medications that have historically been excluded from Part D (Medicare's outpatient drug benefit) — a symbolically important shift with real implications for pharmaceutical revenue models.
The political layer adds uncertainty: House Democrats published a 105-page report on June 23, 2026 — titled Abandoning Americans to Disease — based on interviews with more than 80 sources, alleging the Trump administration disrupted $16 billion in research funding and enabled what the report characterizes as the worst measles crisis in more than 30 years. Representative Robert Garcia, House Oversight Ranking Member, stated that the administration "has gutted scientific medical research, taken away vaccines, and made our families sicker." Whether or not that framing proves durable, it signals Democratic oversight priorities should the party regain a House majority after November 2026 midterms. Congressional primary results on June 24, 2026 added another variable: Representative Adriano Espaillat (D-N.Y.), the Appropriations Ranking Member, lost his primary alongside Representative Dan Goldman (D-N.Y.) — turnover on key spending committees mid-cycle creates real timeline uncertainty for health funding.
Three Things Worth Watching Over the Next 90 Days
Cassidy's proposal is a discussion draft — an opening bid, not a bill with a vote scheduled. Watch for Senate HELP Committee hearings and formal hospital association responses through late summer 2026. The American Hospital Association's pushback on H.R. 9504 signals active lobbying pressure. Investors with exposure to hospital systems, health REITs (real estate investment trusts that own medical facilities), or pharmacy benefit managers should track whether the contract pharmacy cap survives negotiation.
The proposed $299.55 per-treatment base rate for CY 2027 is a proposal pending public comment. CMS will finalize the rule later in 2026. For anyone holding positions in dialysis-related companies through their financial planning or retirement accounts, the final treatment of the AKI payment increase (proposed at 6.0%) and phosphate binder inclusion is worth reading in the Federal Register notice CMS-2026-12925 once finalized.
As of July 1, 2026, the CMS Medicare GLP-1 Bridge Program opens a new Medicare coverage pathway for weight-loss drugs historically excluded from Part D. Early utilization figures — expected in Q3 2026 CMS data releases — will indicate whether this is a narrow pilot or a meaningful market expansion for GLP-1 manufacturers. The answer has direct revenue implications for pharmaceutical companies with major GLP-1 drug portfolios.
Frequently Asked Questions
What is the 340B drug pricing program and how does it work for patients?
The 340B program requires drug manufacturers to sell medications to qualifying healthcare providers at significant discounts. Eligible providers — including safety-net hospitals and federally qualified health centers — can then dispense those drugs at or near regular prices, using the margin to fund additional services for underserved patients. As of 2024, the program covered more than 42,000 covered entities across 53,000-plus care sites, with total drug purchases reaching $81 billion annually, according to HRSA and Senate HELP Committee data current through June 2026.
Why is Congress reforming the 340B program in 2026 after 15 years?
The program has grown dramatically — from $66.3 billion in 2023 to $81 billion in 2024 — and critics argue that much of the financial benefit flows to large health systems rather than directly to low-income patients. Disputes over contract pharmacy arrangements have generated conflicting court rulings across multiple circuits, and HRSA's own reform pilot was vacated by a federal court in February 2026. Senator Cassidy's June 25, 2026 discussion draft aims to establish clearer federal rules, including a five-contract-pharmacy maximum and penalties up to double the discount amount for violations.
How does the FDA clinical trial approval timeline compare to China, and what is Operation Trailblazer?
China surpassed the United States in total registered clinical trials — with more than 7,100 trials representing 39% of global activity — and in Phase 1 trial volume, a shift that began in 2021. HHS launched Operation Trailblazer on June 22, 2026, targeting the FDA's IND (Investigational New Drug) review process — the approval required before beginning human clinical trials — with a projected time savings of six to twelve months per application. The FDA launched a complementary Phase 1 IND Navigator centralized webpage on June 26, 2026, consolidating CDER and CBER guidance resources.
In my analysis, the most underappreciated thread in this week's policy cascade isn't the 340B proposal itself — it's the convergence. When hospitals face Medicaid cuts, contract pharmacy caps, site-neutral payment pressure, and a transparency bill simultaneously, incremental adjustments stop being sufficient. Add a $76 billion Medicare Advantage overpayment problem that MedPAC keeps flagging and a clinical trial competitiveness gap with China that's now five years old, and the conditions for structural healthcare reform — not just annual rate tweaks — are more present than at any point since the ACA debate. That doesn't guarantee action, but it does make the next twelve months in health policy worth watching more carefully than usual.
Disclaimer: This article is editorial commentary intended for informational purposes only and does not constitute financial, legal, or medical advice. All figures cited are sourced from publicly available government, congressional, and industry documents as described in the body. Consult a qualified financial or legal professional before making decisions based on regulatory developments discussed here. Research based on publicly available sources current as of July 1, 2026.